Lilrb2-specific monoclonal antibodies and methods of their use
AssigneeBoard of Regents, The University of Texas System
InventorsZhiqiang AN, Ningyan ZHANG, Peng ZHAO
Life of this patent
Estimating the term…
Abstract
Isolated or recombinant anti-LILRB2 monoclonal antibodies are provided. In some embodiments, the antibodies herein can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as Alzheimer's Disease. In further aspects, the LILRB2-binding antibodies can affect cellular signaling mediated through at least the oA and PS-mediated TREM2 and LILRB2 co-ligation signaling pathway and can be used to modulate microglia function.
Claims13
An isolated monoclonal antibody, wherein the antibody specifically binds to LILRB2 and wherein the antibody competes for binding of the LILRB2 epitopes with a NeuB2-8, NeuB2-9, NeuB2-13, NeuB2-19, NeuB2-29, NeuB2-37, NeuB2-40, NeuB2-55, NeuB2-60, NeuB2-80, NeuB2-93, NeuB2-110, or NeuB2-128 monoclonal antibody.
A chimeric antigen receptor comprising an antigen-binding domain at least 80% identical to an antigen-binding domain of the monoclonal antibody of any one of the preceding claims.
(canceled)
Dependencies are inferred from the claim text.